On CNBC's "Options Action," Mike Khouw spoke about unusually high options activity in Biogen Inc (NASDAQ:BIIB). He noticed on both Tuesday and Wednesday that puts outpaced calls by about 2 to 1.

See Also: Target Option Traders Turn Bearish Following Big Holiday Shopping Weekend

The market is implying a move of 7% in either direction this week when the company is going to release the latest clinical trial results. During the session on Wednesday, Khouw noticed a big activity in the December weekly, $275 puts, which traded for $4.26. The trade breaks even at $270.74 or 5.61% below the current stock price.

Editor's note: The company's clinical trial results are expected Thursday morning and had not yet been published at time of writing.